JAKPOT T1D

11 Aug JAKPOT T1D

For people age 12 – 35 years who have been diagnosed with type 1 diabetes in the past 3 months, this study tests two JAK inhibitors (abrocitinib and ritlecitinib) to see if either or both can preserve insulin production.

TrialNet researchers are testing two different JAK inhibitors – abrocitinib and ritlecitinib – to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).

JAK inhibitors are a new type of treatment researchers are studying in people who have autoimmune conditions. Researchers believe abrocitinib and ritlecitinib may be able to calm the immune system response that harms insulin-producing beta cells in the pancreas. Continuing to make even a small amount of insulin helps keep blood glucose levels in the normal range, lowering the risk of long-term complications.

To understand which treatment works best, participants will be randomly assigned to one of three groups: one will get abrocitinib, one will get ritlecitinib, and one will get a matching placebo (looks like a study drug but has no active ingredients).

JAKPOT is a two-year study. For the first year, you will take an oral tablet daily and visit a study site every three months for tests and monitoring. For the second year, you will no longer take treatment and will have follow-up clinic visits every six months.

Participants in the study will receive personalized coaching in diabetes management.
Study visits take place at our Clinical Research Center in Seattle, and at other TrialNet sites across the US.

https://www.trialnet.org/our-research/newly-diagnosed-t1d/jakpot-t1d

Participant Eligibility

-Age 12-35
-Newly diagnosed with T1D (in past 3 months)
-Up to date on required vaccines (including the flu vaccine when it is available)
-Not pregnant, breastfeeding or planning to become pregnant while in the study

AND have:
-One or more diabetes-related autoantibodies
-Hemoglobin A1C below 10%
-C-peptide detectable during a mixed-meal tolerance test (MMTT)
-These are the study’s main eligibility criteria. A member of your research team will review the full list of criteria with you prior to your screening visit.

Contact

the BRI Outreach Team
(800) 888-4187